CTLA4 and non-small cell lung carcinoma: Wu and Coll investigated the efficacy of CTLA-4 and PD-1 inhibitors vs. other therapies and demonstrated a better PFS and OS in males vs. females; however, these findings were not significant in the NSCLC cohort of the analysis [107].